{
  "id": 10526249,
  "title": "SI-Bone stock gains after FDA clears spinal fusion system",
  "url": "https://urgent.news/2026/09/28/si-bone-stock-gains-after-fda-clears-spinal-fusion-system",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-28T20:21:32.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/sibone-stock-gains-after-fda-clears-spinal-fusion-system-4921136"
  },
  "original_language": "en",
  "account": "Si-Bone Inc (NASDAQ:SIBN) shares surged 2.8% in after-hours trading on Monday after the company announced it had received U.S. Food and Drug Administration (FDA) clearance for its iFuse Granite Onyx System. This marks the first product from Si-Bone targeting compromised bone for use outside the pelvis, broadening the company's market potential beyond its current pelvic applications. The innovative technology boasts a surface tailored to bone density and a thread form customized to specific anatomy. This design aims to facilitate swift osseointegration and minimize micromotion, ultimately leading to earlier fixation and a reduction in screw loosening. Dr. Han Jo Kim, a prominent spine surgeon from the Hospital for Special Surgery, emphasized the critical need for a solution to address screw loosening in spinal fusions, particularly at the UIV and LIV levels. Laura Francis, Si-Bone's CEO, announced that Onyx is the company's third device designated as a breakthrough by the FDA. Since its inception in 2009, Si-Bone has supported over 150,000 procedures performed by its physicians. The company, headquartered in San Jose, California, focuses on developing solutions to tackle clinical challenges linked to compromised bone, with a specific emphasis on the spinopelvic anatomy.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}